HomeCompareOBSV vs ORCC

OBSV vs ORCC: Dividend Comparison 2026

OBSV yields 1964.64% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBSV wins by $8418661323.98M in total portfolio value
10 years
OBSV
OBSV
● Live price
1964.64%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8418661324.00M
Annual income
$7,652,437,982,425,691.00
Full OBSV calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — OBSV vs ORCC

📍 OBSV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBSVORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBSV + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBSV pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBSV
Annual income on $10K today (after 15% tax)
$166,994.11/yr
After 10yr DRIP, annual income (after tax)
$6,504,572,285,061,837.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, OBSV beats the other by $6,504,572,285,061,836.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBSV + ORCC for your $10,000?

OBSV: 50%ORCC: 50%
100% ORCC50/50100% OBSV
Portfolio after 10yr
$4209330662.01M
Annual income
$3,826,218,991,212,846.00/yr
Blended yield
90.90%
📊

Analyst Conviction Gap

Where Wall Street is split right now

OBSV
Analyst Ratings
9
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$6.00
+5793.9% upside vs current
Range: $6.00 — $6.00
Altman Z
-39.0
Piotroski
4/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBSV buys
0
ORCC buys
0
No recent congressional trades found for OBSV or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBSVORCC
Forward yield1964.64%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$8418661324.00M$21.4K
Annual income after 10y$7,652,437,982,425,691.00$1.04
Total dividends collected$8364201739.80M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$6.00$16.00

Year-by-year: OBSV vs ORCC ($10,000, DRIP)

YearOBSV PortfolioOBSV Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$207,164$196,463.65$11,190$489.61+$196.0KOBSV
2$4,025,415$3,803,750.33$12,229$256.01+$4.01MOBSV
3$73,382,907$69,075,712.04$13,216$130.74+$73.37MOBSV
4$1,255,382,398$1,176,862,688.09$14,207$66.02+$1255.37MOBSV
5$20,159,078,828$18,815,819,662.20$15,234$33.17+$20159.06MOBSV
6$303,950,265,341$282,380,050,994.39$16,317$16.62+$303950.25MOBSV
7$4,304,301,356,343$3,979,074,572,429.02$17,468$8.32+$4304301.34MOBSV
8$57,267,735,234,320$52,662,132,783,032.35$18,695$4.16+$57267735.22MOBSV
9$716,096,580,908,859$654,820,104,208,136.60$20,006$2.08+$716096580.89MOBSV
10$8,418,661,323,998,170$7,652,437,982,425,691.00$21,407$1.04+$8418661323.98MOBSV

OBSV vs ORCC: Complete Analysis 2026

OBSVStock

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Full OBSV Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this OBSV vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBSV vs SCHDOBSV vs JEPIOBSV vs OOBSV vs KOOBSV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.